TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27560549

Group type: EXPERIMENTAL
Intervention: Docetaxel (8 or more cycles)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Docetaxel (more than 10 cycles)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Docetaxel (8 to 10 cycles)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Docetaxel (5 to 7 cycles)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Docetaxel (4 or fewer cycles)
Number of subjects: 1059
Study: 25201903

Group type: EXPERIMENTAL
Intervention: LigaSure group (Subgroup g: 3 bars-power levels/1 frequency application)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stapler group
Number of subjects: 100
Study: 23466360

Group type: EXPERIMENTAL
Intervention: IUS V285 at 0.4%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IUS V35 at 99%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EUS V240 at 63%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IUS V35 at 95%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EUS V265 at 24%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IUS V35 at 99.5%
Number of subjects: 42
Study: 21519001

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20053262

Group type: EXPERIMENTAL
Intervention: Group 1 (two explanatory illustrations)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2 (four explanatory illustrations)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3 (5-minute video and handling)
Number of subjects: 80
Study: 16963041

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with PCOS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fasting glucose, fasting insulin, body mass index, and free T in patients with PCOS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Parameters controlled for body mass index
Number of subjects: 38
Study: 15690112

Group type: EXPERIMENTAL
Intervention: Preparation stage of change
Number of subjects: 181

Group type: COMPARATOR
Intervention: Contemplation stage of change
Number of subjects: 181
Study: 11400799

Group type: EXPERIMENTAL
Intervention: 0.2% GTN
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9417802

Group type: EXPERIMENTAL
Intervention: Gamma delta T cell expansion in patients with CP (11.1 +/- 11.0%)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Persistent gamma delta T cell expansion over 15% in 15 patients
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: V gamma II/V delta 2-dominant expansion
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: V delta 1-dominant expansion
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Unusual expansions of V delta 4 and V delta 6
Number of subjects: 205
Study: 8494429

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 3732367

Group type: EXPERIMENTAL
Intervention: Theo-Dur (theophylline only)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phyllocontin (aminophylline)
Number of subjects: 12
Study: 30322782

Group type: EXPERIMENTAL
Intervention: Treadmill workstations for optional use
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sit-stand desks as usual (Control)
Number of subjects: 80
Study: 27048405

Group type: EXPERIMENTAL
Intervention: PCT-guided therapy
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: PCT and CRP
Number of subjects: 550
Study: 23702257

Group type: EXPERIMENTAL
Intervention: 9.6% carbohydrate‐caffeine‐electrolyte solution with carbohydrate‐electrolyte gels (H‐CHO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5.6% carbohydrate‐electrolyte solution with electrolyte gels (CHO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Electrolyte solution and electrolyte gels (PL)
Number of subjects: 14
Study: 22184384

Group type: COMPARATOR
Intervention: XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: XP/XRT/XP (two cycles of XP followed by 45-Gy XRT with capecitabine 1,650 mg/m2 per day for 5 weeks and two cycles of XP)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: XP/XRT/XP
Number of subjects: 458
Study: 19883407

Group type: EXPERIMENTAL
Intervention: Scheduled maintenance treatment with infliximab (5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (immunomodulators and/or corticosteroids)
Number of subjects: 0
Study: 18762502

Group type: EXPERIMENTAL
Intervention: Antichlamydial antimicrobial exposure events (macrolide, tetracycline, quinolone, rifamycin)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Antichlamydial antimicrobial exposure events
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: C-reactive protein level
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Recurrent antichlamydial treatments
Number of subjects: 508
Study: 15811637

Group type: EXPERIMENTAL
Intervention: Flywheel resistive exercise (FW)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pamidronate (Pam)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 25
Study: 8749726

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg, p.o.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg, p.o.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fluoxetine (60 mg, p.o.)
Number of subjects: 21
Study: 2049233

Group type: EXPERIMENTAL
Intervention: Nifedipine, sparteine and phenytoin administered as a 'cocktail'
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single substrate administration of nifedipine, sparteine and phenytoin
Number of subjects: 8
Study: 7452209

Group type: EXPERIMENTAL
Intervention: Subliminal message 'mommy and I are one'
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group with subliminal message 'people are walking'
Number of subjects: 34
Study: 31914094

Group type: EXPERIMENTAL
Intervention: Modified long-axis in-plane ultrasound technique (M-LAINUT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conventional palpation technique (C-PT)
Number of subjects: 288
Study: 30801820

Group type: EXPERIMENTAL
Intervention: 5-minute scrub with Betadine (povidone-iodine)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 10-minute scrub with Betadine (povidone-iodine)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Comparison of 5-minute vs 10-minute scrub
Number of subjects: 101
Study: 28337660

Group type: COMPARATOR
Intervention: Perioperative ECF chemotherapy alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perioperative ECF chemotherapy with preoperative chemoradiation
Number of subjects: 120
Study: 25765043

Group type: EXPERIMENTAL
Intervention: GON blockade with bupivacaine (group B)
Number of subjects: 84

Group type: COMPARATOR
Intervention: GON blockade with saline (group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: GON blockade with bupivacaine (group B) after blinding removed
Number of subjects: 84

Group type: COMPARATOR
Intervention: GON blockade with saline (group A) after blinding removed
Number of subjects: 84
Study: 24014503

Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT) using InSight software for 20 hours
Number of subjects: 87

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 87
Study: 20490455

Group type: EXPERIMENTAL
Intervention: Structured patient-clinician communication
Number of subjects: 507
Study: 19748858

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 37
Study: 17404192

Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 15523532

Group type: EXPERIMENTAL
Intervention: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during acute hemiplegia (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during chronic hemiplegia (Group B)
Number of subjects: 41
Study: 11705338

Group type: EXPERIMENTAL
Intervention: Tape of music with supra- and subliminal messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tape of music with only subliminal messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tape with only music (participants believed it included subliminal messages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting group (no tapes)
Number of subjects: 0
Study: 9043724

Group type: EXPERIMENTAL
Intervention: Neutrophil-specific filter
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard blood filter
Number of subjects: 24
Study: 7710234

Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine/fentanyl
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuous intravenous fentanyl
Number of subjects: 51
Study: 2901267

Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg daily for 3 weeks to 56 months)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Terazosin in combination with other antihypertensive agents
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Adverse effects of Terazosin
Number of subjects: 364
Study: 31761974

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30497559

Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 100

Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deferred lesions (n=24)
Number of subjects: 100
Study: 26922379

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans MTCC 5856 tablet containing 2 × 10(9) cfu/day for 90 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25693859

Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg (with optional titration to 200 and 400 mg)
Number of subjects: 32
Study: 23617229

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% ophthalmic solution applied daily for 9 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle applied nightly for 5 months, followed by re-randomization to either Bimatoprost (Veh-Bim Group) or Vehicle (Veh Group) for 4 months
Number of subjects: 20
Study: 20950189

Group type: EXPERIMENTAL
Intervention: Diamond bur
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air‐abrasion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er, Cr: YSGG laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 17601603

Group type: EXPERIMENTAL
Intervention: GnRH‐a/chemotherapy
Number of subjects: 115
Study: 16615418

Group type: EXPERIMENTAL
Intervention: Stable hypoxemic COPD (HC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stable nonhypoxemic COPD (NHC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 28
Study: 12816781

Group type: EXPERIMENTAL
Intervention: Isolated soy protein with isoflavones
Number of subjects: 28

Group type: COMPARATOR
Intervention: Total milk protein
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ethanol-washed isolated soy protein with trace isoflavones
Number of subjects: 28
Study: 11386482

Group type: EXPERIMENTAL
Intervention: Speech Motor Training (SMT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extended Length of Utterance (ELU)
Number of subjects: 12
Study: 8860064

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1298143

Group type: EXPERIMENTAL
Intervention: 400 mg Bezafibrate retard
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 20 to 80 mg Lovastatin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 6734453

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and carmustine (FB)
Number of subjects: 77

Group type: COMPARATOR
Intervention: 5-fluorouracil, carmustine, and adriamycin (FAB)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both FB and FAB
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FAB
Number of subjects: 77
Study: 31239111

Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg per day) for 3 months
Number of subjects: 182

Group type: COMPARATOR
Intervention: Solifenacin (5 mg per day) for 6 months
Number of subjects: 182
Study: 28729200

Group type: EXPERIMENTAL
Intervention: Thicker and creamier test drink (enhanced sensory - ES)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Thinner test drink (low sensory - LS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Test recall condition
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control recall condition
Number of subjects: 119
Study: 25889642

Group type: EXPERIMENTAL
Intervention: Standalone web-based ECG tutorial
Number of subjects: 203

Group type: COMPARATOR
Intervention: Short follow-up (2-4 weeks)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Medium follow-up (10-12 weeks)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Long follow-up (18-20 weeks)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Junior students
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Senior students
Number of subjects: 203
Study: 24001575

Group type: EXPERIMENTAL
Intervention: Ipsilateral hamstring tendon autograft (semitendinosus gracilis)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Contralateral hamstring tendon autograft (semitendinosus gracilis)
Number of subjects: 100
Study: 21366801

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine
Number of subjects: 596

Group type: COMPARATOR
Intervention: Monovalent hepatitis A and B vaccines
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Additional dose of the same vaccine(s) used for priming
Number of subjects: 596
Study: 19479879

Group type: EXPERIMENTAL
Intervention: Serum interferon-alpha activity in untreated juvenile DM patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum interferon-alpha activity at 36 months postdiagnosis
Number of subjects: 39
Study: 17166866

Group type: EXPERIMENTAL
Intervention: Surgical abortion
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Medical abortion (mifepristone-misoprostol)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both interventions (surgical and medical)
Number of subjects: 78
Study: 15094269

Group type: EXPERIMENTAL
Intervention: Nevirapine 400 mg once daily
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg twice daily
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg once daily
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Nevirapine (400 mg) and efavirenz (800 mg) once daily
Number of subjects: 1216

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Nevirapine plus efavirenz
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Nevirapine once daily
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Nevirapine or efavirenz
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Combination of nevirapine and efavirenz
Number of subjects: 1216
Study: 11701687

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg daily)
Number of subjects: 134
Study: 9771244

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (for both phases)
Number of subjects: 43
Study: 7909285

Group type: EXPERIMENTAL
Intervention: Salmeterol 10.5 micrograms
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salmeterol 21 micrograms
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salmeterol 84 micrograms
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salmeterol (all doses)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 3281702

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (Protocol D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 60
Study: 31028669

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other second-generation BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversible BTK inhibitors (vecabrutinib, LOXO-305)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-selective reversible BTK inhibitors (ARQ-531)
Number of subjects: 0
Study: 28504364

Group type: EXPERIMENTAL
Intervention: Long-term mindfulness meditation (LTM) practice; participants practiced mindfulness meditation just prior to observing others' social pain.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched with LTM practitioners); no specific intervention mentioned.
Number of subjects: 0
Study: 26556092

Group type: EXPERIMENTAL
Intervention: Experimental Wii Group (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Exercise Group (n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 23438494

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment after standard diabetes education
Number of subjects: 699
Study: 21531174

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg once a day for 7 days)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Chloramphenicol (75 mg/kg per day in four divided doses for 14 days)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 844

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 844
Study: 18294485

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 55
Study: 17136556

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (e.g., natalizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant beta-interferons and glatiramer acetate (Copaxone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN-beta1b (Betaferon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study: 12937343

Group type: EXPERIMENTAL
Intervention: Fertilase-laser system technology
Number of subjects: 356
Study: 11084095

Group type: EXPERIMENTAL
Intervention: Dual-site pacing (Group I)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Single-site (high right atrium) pacing (Group II)
Number of subjects: 26
Study: 9342766

Group type: EXPERIMENTAL
Intervention: High-dose hypericum extract
Number of subjects: 209

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 209
Study: 7901064

Group type: EXPERIMENTAL
Intervention: ethinylestradiol/cyproterone acetate (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: D-Tr-6-LHRH (group B)
Number of subjects: 45
Study: 3513716

Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms intranasal nightly for three months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Enuresis alarm (for three months)
Number of subjects: 46
Study: 31858113

Group type: EXPERIMENTAL
Intervention: Preconception marine PUFA concentration
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Preconception SFA concentration
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Preconception trans FA concentration
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: FAs at 8 weeks of gestation
Number of subjects: 346
Study: 30815063

Group type: EXPERIMENTAL
Intervention: Capturing healthy meals
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Capturing unhealthy meals
Number of subjects: 22
Study: 27618460

Group type: EXPERIMENTAL
Intervention: CIL condition (peer-delivered core services of Centers for Independent Living)
Number of subjects: 99

Group type: COMPARATOR
Intervention: SAU condition (services as usual)
Number of subjects: 99
Study: 24911028

Group type: EXPERIMENTAL
Intervention: Buspirone titrated to 60 mg/d
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Buspirone (female participants)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (female participants)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Buspirone (male participants)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (male participants)
Number of subjects: 62
Study: 22731873

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg) every 4 hours for up to 10 days
Number of subjects: 282

Group type: COMPARATOR
Intervention: Saline placebo every 4 hours for up to 10 days
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 282
Study: 20176276

Group type: EXPERIMENTAL
Intervention: Autofluorescence inspection
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard panendoscopy
Number of subjects: 66
Study: 18585835

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/d for 12 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 36
Study: 15951467

Group type: EXPERIMENTAL
Intervention: Azimilide coadministered with digoxin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Digoxin coadministered with azimilide
Number of subjects: 18
Study: 12207874

Group type: EXPERIMENTAL
Intervention: racemic bupivacaine (0.5% as salt)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: S‐bupivacaine (0.5% as base)
Number of subjects: 6